An Open-label, Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma

Trial Profile

An Open-label, Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Pirarubicin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide phosphate; Ifosfamide; Methotrexate; Prednisone; Vincristine
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Nov 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2018.
    • 10 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top